We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals

196 hedge funds and large institutions have $704M invested in ANI Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 82 increasing their positions, 51 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 13

61% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 51

30% more capital invested

Capital invested by funds: $543M → $704M (+$161M)

16% more call options, than puts

Call options by funds: $7.06M | Put options by funds: $6.07M

6.23% more ownership

Funds ownership: 65%71.23% (+6.2%)

3% more funds holding

Funds holding: 190196 (+6)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
196
Holders Change
+6
Holders Change %
+3.16%
% of All Funds
4.26%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
21
Increased
82
Reduced
51
Closed
13
Calls
$7.06M
Puts
$6.07M
Net Calls
+$997K
Net Calls Change
-$2.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Principal Financial Group
26
Principal Financial Group
Iowa
$5.88M +$342K +4,807 +7%
Allianz Asset Management
27
Allianz Asset Management
Germany
$5.13M -$48.4K -681 -1%
Wells Fargo
28
Wells Fargo
California
$4.91M +$1.89M +26,639 +81%
OAM
29
Oxford Asset Management
United Kingdom
$4.5M +$3.17M +44,571 +436%
MSL
30
Mackay Shields LLC
New York
$3.97M +$3.08M +43,314 +864%
CEP
31
Chicago Equity Partners
Illinois
$3.9M -$21.3K -300 -0.6%
ACM
32
Argent Capital Management
Missouri
$3.88M +$464K +6,520 +16%
WAM
33
Weiss Asset Management
Massachusetts
$3.87M -$2.31M -32,517 -41%
Goldman Sachs
34
Goldman Sachs
New York
$3.8M -$635K -8,935 -16%
MAM
35
Martingale Asset Management
Massachusetts
$3.5M +$1.1M +15,502 +57%
CCM
36
Cadence Capital Management
Massachusetts
$3.31M -$1.45M -20,346 -34%
Morgan Stanley
37
Morgan Stanley
New York
$3.23M +$2.36M +33,208 +550%
RIM
38
Regent Investment Management
Kentucky
$3.21M -$287K -4,030 -9%
PPA
39
Parametric Portfolio Associates
Washington
$2.63M +$484K +6,802 +27%
PCM
40
Perkins Capital Management
Minnesota
$2.45M -$196K -2,750 -8%
SCP
41
Seizert Capital Partners
Michigan
$2.42M +$2.09M +29,397 New
Skandinaviska Enskilda Banken (SEB)
42
Skandinaviska Enskilda Banken (SEB)
Sweden
$2.35M -$1.1M -15,500 -35%
GC
43
Globeflex Capital
California
$2.28M
DIA
44
Dana Investment Advisors
Wisconsin
$2.22M -$218K -3,064 -10%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$2.18M +$173K +2,436 +10%
RHJA
46
Rice Hall James & Associates
California
$2.16M -$114K -1,600 -6%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$2.09M +$139K +1,958 +8%
New York State Teachers Retirement System (NYSTRS)
48
New York State Teachers Retirement System (NYSTRS)
New York
$2.08M +$32.1K +452 +2%
1CM
49
1492 Capital Management
Wisconsin
$2.07M -$36.3K -510 -2%
GCP
50
GSA Capital Partners
United Kingdom
$2.07M +$96.2K +1,353 +6%

ANIP Hedge Fund Activity: Q2 2019 in Review

196 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2019, worth a combined $704M — up 30% from $543M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ANIP positions and 13 closed out — a net gain of 8 holders — while 82 added to existing stakes and 51 trimmed.

The largest buyer was Invesco, adding an estimated $8.11M. The largest seller was SG Americas Securities, cutting an estimated $4.21M.

  • 196 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2019, up from 190 in Q1 2019.
  • Funds reported $704M of ANI Pharmaceuticals stock for Q2 2019, up 30% quarter-over-quarter.
  • 21 funds opened new ANI Pharmaceuticals positions in Q2 2019 and 13 closed out, a net change of +8 holders.
  • The largest ANI Pharmaceuticals buyer in Q2 2019 was Invesco, an estimated $8.11M added.
  • The largest ANI Pharmaceuticals seller in Q2 2019 was SG Americas Securities, an estimated $4.21M sold.

Based on aggregated 13F filings for Q2 2019.